Vanguard Capital Management
LFCR icon

Vanguard Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Vanguard Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.77M Sell
1,288,621
-1,515
-0.1% -$7.63K ﹤0.01% 3003
2026
Q1 		$4.8M Buy
+1,290,136
New +$8.91M ﹤0.01% 3078

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Vanguard Capital Management's LFCR Position: Q2 2026 in Review

Vanguard Capital Management reduced its Lifecore Biomedical (LFCR) stake by 0.12% in Q2 2026, selling an estimated $7.63K and leaving 1,288,621 shares worth $6.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

Vanguard Capital Management first reported a position in LFCR in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Vanguard Capital Management held 1,288,621 shares of Lifecore Biomedical worth $6.77M as of Q2 2026.
  • Vanguard Capital Management sold 1,515 Lifecore Biomedical shares in Q2 2026, an estimated $7.63K.
  • Lifecore Biomedical made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3003 holding.
  • Vanguard Capital Management first reported a position in Lifecore Biomedical in Q1 2026 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.